Background: Fetal macrosomia, defined as a birth weight ≥4,000 g, may affect 12% of newborns of normal women and 15-45% of newborns of women with gestational diabetes mellitus (GDM). The increased risk of macrosomia in GDM is mainly due to the increased insulin resistance of the mother. In GDM, a higher amount of blood glucose passes through the placenta into the fetal circulation. As a result, extra glucose in the fetus is stored as body fat causing macrosomia, which is also called ‘large for gestational age'. This paper reviews studies that explored the impact of GDM and fetal macrosomia as well as macrosomia-related complications on birth outcomes and offers an evaluation of maternal and fetal health. Summary: Fetal macrosomia is a common adverse infant outcome of GDM if unrecognized and untreated in time. For the infant, macrosomia increases the risk of shoulder dystocia, clavicle fractures and brachial plexus injury and increases the rate of admissions to the neonatal intensive care unit. For the mother, the risks associated with macrosomia are cesarean delivery, postpartum hemorrhage and vaginal lacerations. Infants of women with GDM are at an increased risk of becoming overweight or obese at a young age (during adolescence) and are more likely to develop type II diabetes later in life. Besides, the findings of several studies that epigenetic alterations of different genes of the fetus of a GDM mother in utero could result in the transgenerational transmission of GDM and type II diabetes are of concern.

Journal Section:
Over- and Undernutrition
Keywords:
Gestational diabetes mellitus, Large for gestational age, Macrosomia, Hyperglycemia, Obesity, Pregnancy, Epigenetics
1.
Ehrenberg HM, Mercer BM, Catalano PM: The influence of obesity and diabetes on the prevalence of macrosomia. Am J Obstet Gynecol 2004;191:964-968.
[PubMed]
https://doi.org/10.1016/j.ajog.2004.05.052
2.
Yogev Y, Langer O: Pregnancy outcome in obese and morbidly obese gestational diabetic women. Eur J Obstet Gynecol Reprod Biol 2008;137:21-26.
[PubMed]
https://doi.org/10.1016/j.ejogrb.2007.03.022
3.
Jovanovic-Peterson L, Peterson CM, Reed GF, Metzger BE, Mills JL, Knopp RH, et al: Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development-Diabetes in Early Pregnancy Study. Am J Obstet Gynecol 1991;164:103-111.
[PubMed]
https://doi.org/10.1016/0002-9378(91)90637-7
4.
McFarland MB, Trylovich CG, Langer O: Anthropometric differences in macrosomic infants of diabetic and nondiabetic mothers. J Matern Fetal Med 1998;7:292-295.
[PubMed]
https://doi.org/10.1002/(SICI)1520-6661(199811/12)7:6<292::AID-MFM7>3.0.CO;2-A
5.
Athukorala C, Crowther CA, Willson K: Women with gestational diabetes mellitus in the ACHOIS trial: risk factors for shoulder dystocia. Aust NZ J Obstet Gynaecol 2007;47:37-41.
[PubMed]
https://doi.org/10.1111/j.1479-828X.2006.00676.x
6.
Hunter DJ, Burrows RF, Mohide PT, Whyte RK: Influence of maternal insulin-dependent diabetes mellitus on neonatal morbidity. CMAJ 1993;149:47-52.
[PubMed]
7.
Simmons D: Interrelation between umbilical cord serum sex hormones, sex hormone-binding globulin, insulin-like growth factor I, and insulin in neonates from normal pregnancies and pregnancies complicated by diabetes. J Clin Endocrinol Metab 1995;80:2217-2221.
[PubMed]
https://doi.org/10.1210/jcem.80.7.7608282
8.
Ryan EA, Enns L: Role of gestational hormones in the induction of insulin resistance. J Clin Endocrinol Metab 1998;67:341-347.
[PubMed]
https://doi.org/10.1210/jcem-67-2-341
9.
Ahmed SA, Shalayel MH: Role of cortisol in the deterioration of glucose tolerance in Sudanese pregnant women. East Afr Med J 1999;76:465-467.
[PubMed]
10.
Buchanan TA, Xiang AH: Gestational diabetes mellitus. J Clin Invest 2005;115:485-491.
[PubMed]
https://doi.org/10.1172/JCI24531
11.
Catalano PM: Obesity, insulin resistance, and pregnancy outcome. Reproduction 2010;140:365-371.
[PubMed]
https://doi.org/10.1530/REP-10-0088
12.
Briana DD, Malamitsi-Puchner A: Reviews: adipocytokines in normal and complicated pregnancies. Reprod Sci 2009;16:921-937.
[PubMed]
https://doi.org/10.1177/1933719109336614
13.
Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994;91:4854-4858.
[PubMed]
https://doi.org/10.1073/pnas.91.11.4854
14.
Hotamisligil GS, Peraldi P, Budavari A, et al: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science 1996;271:665-668.
[PubMed]
https://doi.org/10.1126/science.271.5249.665
15.
Al-Noaemi M, Shalayel MHF: Adiponectin. Sudan J Med Sci 2009;4:297-305.
16.
Lazer S, Biale Y, Mazor M et al: Complications associated with the macrosomic fetus. J Reprod Med 1986;31:501-505.
[PubMed]
17.
Haji-Ebrahim-Tehrani F, Kazemi H, Kordi M: Prevalence and outcome of the macrosomic infants. Acta Med Iranica 2007;45:505-509.
18.
McFarland LV, Raskin M, Daling JR, Benedetti TJ: Erb/Duchenne's palsy: a consequence of fetal macrosomia and method of delivery. Obstet Gynecol 1986;68:784-788.
[PubMed]
19.
Pettitt DJ, Nelson RG, Saad MF, Bennett PH, Knowler WC: Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy. Diabetes Care 1993;16:310-314.
[PubMed]
https://doi.org/10.2337/diacare.16.1.310
20.
Crume TL, Ogden L, West NA, et al: Association of exposure to diabetes in utero with adiposity and fat distribution in a multiethnic population of youth: the Exploring Perinatal Outcomes among Children (EPOCH) study. Diabetologia 2011;54:87-92.
[PubMed]
https://doi.org/10.1007/s00125-010-1925-3
21.
Crume TL, Ogden L, Daniels S, Hamman RF, Norris JM, Dabelea D: The impact of in utero exposure to diabetes on childhood body mass index growth trajectories: the EPOCH study. J Pediatr 2011;158:941-946.
[PubMed]
https://doi.org/10.1016/j.jpeds.2010.12.007
22.
Barker DJ, Eriksson JG, Forsén T, Osmond C: Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol 2002;31:1235-1239.
[PubMed]
https://doi.org/10.1093/ije/31.6.1235
23.
Gillman MW: Developmental origins of health and disease. N Engl J Med 2005;353:1848-1850.
[PubMed]
https://doi.org/10.1056/NEJMe058187
24.
Wolffe AP, Guschin D: Review: chromatin structural features and targets that regulate transcription. J Struct Biol 2000;129:102-122.
[PubMed]
https://doi.org/10.1006/jsbi.2000.4217
25.
Handel AE, Ebers GC, Ramagopalan SV: Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med 2010;16:7-16.
[PubMed]
https://doi.org/10.1016/j.molmed.2009.11.003
26.
Bollati V, Baccarelli A: Environmental epigenetics. Heredity 2010;105:105-112.
[PubMed]
https://doi.org/10.1038/hdy.2010.2
27.
Smallwood SA, Kelsey G: De novo DNA methylation: a germ cell perspective. Trends Genet 2012;28:33-42.
[PubMed]
https://doi.org/10.1016/j.tig.2011.09.004
28.
El Hajj N, Pliushch G, Schneider E, Dittrich M, Müller T, Korenkov M, Aretz M, Zechner U, Lehnen H, Haaf T: Metabolic programming of MEST DNA methylation by intrauterine exposure to gestational diabetes mellitus. Diabetes 2013;62:1320-1328.
[PubMed]
https://doi.org/10.2337/db12-0289
29.
Moore TR: Fetal exposure to gestational diabetes contributes to subsequent adult metabolic syndrome. Am J Obstet Gynecol 2010;202:643- 649.
[PubMed]
https://doi.org/10.1016/j.ajog.2010.02.059
30.
Ding GL, Wang FF, Shu J, et al: Transgenerational glucose intolerance with Igf2/H19 epigenetic alterations in mouse islet induced by intrauterine hyperglycemia. Diabetes 2012;61:1133-1142.
[PubMed]
https://doi.org/10.2337/db11-1314
31.
Bouchard L, Hivert M-F, Guay S-P, et&#x2009;al: Placental adiponectin gene DNA methylation levels are associated with mothers' blood glucose concentration. Diabetes 2012;61: 1272-1280.
[PubMed]
https://doi.org/10.2337/db11-1160
32.
Bouchard L, Thibault S, Guay SP, et&#x2009;al: Leptin gene epigenetic adaptation to impaired glucose metabolism during pregnancy. Diabetes Care 2010;33:2436-2441.
[PubMed]
https://doi.org/10.2337/dc10-1024
33.
Uzelac PS, Li X, Lin J, et&#x2009;al: Dysregulation of leptin and testosterone production and their receptor expression in the human placenta with gestational diabetes mellitus. Placenta 2010;31:581-588.
[PubMed]
https://doi.org/10.1016/j.placenta.2010.04.002
34.
Houde A-A, Hivert M-F, Bouchard L: Fetal epigenetic programming of adipokines. Adipocyte 2013;2:41-46.
[PubMed]
https://doi.org/10.4161/adip.22055
35.
Simmons D: Diabetes and obesity in pregnancy. Best Pract Res Clin Obstet Gynaecol 2011;25:25-36.
[PubMed]
https://doi.org/10.1016/j.bpobgyn.2010.10.006
36.
Chu SY, Callaghan WM, Kim SY, et al: Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care 2007;30:2070-2076.
[PubMed]
https://doi.org/10.2337/dc06-2559a
37.
Metzger BE, Lowe LP, Dyer AR, et al: The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: associations of higher levels of maternal glucose and BMI with macrosomia: an example of diabesity. ADA 70th Scientific Session, 2010. Abstract No. 154-OR. http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&amp;CID= 79099.
38.
Ryan EA: Diagnosing gestational diabetes. Diabetologia 2011;54:480-486.
[PubMed]
https://doi.org/10.1007/s00125-010-2005-4
39.
Ricart W, Lopez J, Mozas J, et al: Body mass index has a greater impact on pregnancy outcomes than gestational hyperglycaemia. Diabetologia 2005;48:1736-1742.
[PubMed]
https://doi.org/10.1007/s00125-005-1877-1
40.
Conway DL, Langer O: Elective delivery of infants with macrosomia in diabetic women: reduce shoulder dystocia versus increase cesarean deliveries. Am J Obstet Gynecol 1998;178:922-925.
[PubMed]
https://doi.org/10.1016/S0002-9378(98)70524-1
41.
American College of Obstetricians and Gynecologists Committee on Practice Bulletins - Obstetrics: ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol 2001;98:525-538.
[PubMed]
https://doi.org/10.1080/01443610120072144
42.
Sanchez-Ramos L, Bernstein S, Kaunitz AM: Expectant management versus labor induction for suspected fetal macrosomia: a systematic review. Obstet Gynecol 2002;100:997-1002.
[PubMed]
https://doi.org/10.1016/S0029-7844(02)02321-9
43.
Ott WJ: The diagnosis of altered fetal growth. Obstet Gynecol Clin North Am 1988;15:237-263.
[PubMed]
44.
Cheng YW, Sparks TN, Laros RK, Nicholson JM, Caughey AB: Impending macrosomia: will induction of labour modify the risk of caesarean delivery? BJOG 2012;119:402-409.
[PubMed]
https://doi.org/10.1111/j.1471-0528.2011.03248.x
45.
Friesen CD, Miller AM, Rayburn WF: Influence of spontaneous or induced labor on delivering the macrosomic fetus. Am J Perinatol 1995;12:63-66.
[PubMed]
https://doi.org/10.1055/s-2007-994404
46.
Combs CA, Singh NB, Khoury JC: Elective induction versus spontaneous labor after sonographic diagnosis of fetal macrosomia. Obstet Gynecol 1993;81:492-496.
[PubMed]
https://doi.org/10.1016/0020-7292(94)90050-7
47.
Horrigan TJ: Physicians who induced labor for fetal macrosomia do not reduce cesarean delivery rates. J Perinatol 2001;21:91-96.
[PubMed]
https://doi.org/10.1038/sj.jp.7200500
48.
Hall MH: Guessing the weight of the baby. Br J Obstet Gynaecol 1996;103:734-736.
[PubMed]
https://doi.org/10.1111/j.1471-0528.1996.tb09865.x
49.
Chauhan SP, Grobman WA, Gherman RA, et al: Suspicion and treatment of the macrosomic fetus: a review. Am J Obstet Gynecol 2005;193:332-346.
[PubMed]
https://doi.org/10.1016/j.ajog.2004.12.020
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.